fibrinolytic

(redirected from fibrinolytic agent)
Also found in: Dictionary.
Related to fibrinolytic agent: thrombolytic agent, fibrinolytic inhibitors

fi·bri·no·lyt·ic

(fī'brin-ō-lit'ik),
Denoting, characterized by, or causing fibrinolysis.

fibrinolytic

adjective Referring to or producing fibrinolysis.

fi·bri·no·lyt·ic

(fī'brin-ō-lit'ik)
Denoting, characterized by, or causing fibrinolysis.

fibrinolytic

pertaining to or emanating from fibrinolysis.

fibrinolytic agent
substances that stimulate or inhibit fibrinolysis.
fibrinolytic inhibitors
include ε-aminocaproic acid and antiplasmin-α1.
fibrinolytic mechanism
an ordered sequence of interactions between an enzyme and a cofactor on a specific substrate; the components of the process include plasminogen, tissue plasminogen activator, urokinase and kallikrein.
fibrinolytic stimulators
includes hormones (e.g. corticosteroids), enzymes (e.g. streptokinase) and others such as epinephrine.
fibrinolytic system tests
ways of examining the system include clot lysis time, euglobulin lysis time, fibrin plate test.
References in periodicals archive ?
Only 4 out of a potential 50 patients (8%) received a fibrinolytic agent, all within 20 minutes of seeing a doctor.
This fibrinolytic agent is made with recombinant DNA technology from human melanoma cells that was initially approved in 1996 to treat acute ischemic stroke.
Streptokinase is the least expensive fibrinolytic agent, but because it is a bacterial protein, it has allergic and pyrogenic side effects, particularly with repeated exposure in patients with prior streptococcal infections.
Both groups had similar ages and similar percentages of men, hypertension, diabetes, dyslipidemia, chest pain, and anterior wall infarctions on presentation, the use of streptokinase as the fibrinolytic agent, and similar percentages of TIMI-3 flow restoration, and the need for coronary artery bypass grafting.
presented the results of the Clopidogrel as Adjunctive Reperfusion Therapy--Thrombolysis in Myocardial Infarction trial (CLARITY-TIMI 28), a double-blind study in which 3,491 patients presenting with ST-elevation MI (STEMI) within 12 hours of symptom onset received a fibrinolytic agent, aspirin, and heparin and were then randomized to oral clopidogrel or placebo.
presented the results of the Clopidogrel as Adjunctive ReperfusIon Therapy-Thrombolysis in Myocardial Infarction trial (CLARITY-TIMI 28), a double-blind study in which 3,491 patients presenting with ST-elevation MI (STEMI) within 12 hours of symptom onset received a fibrinolytic agent, aspirin, and heparin and were then randomized to oral clopidogrel or placebo.
Retavase[R] (reteplase) is a fibrinolytic agent that was approved by the U.
for the commercial manufacture of Retavase[R] (reteplase), a fibrinolytic agent that has been marketed in North America since October 1996.
The study evaluated the combination of half the standard dose of the clot-dissolving fibrinolytic agent RETAVASE(R) (reteplase) and a standard dose of ReoPro(R) (abciximab), a drug that prevents the formation of blood clots, as a potential new treatment regimen for heart attack.
Results announced this weekend at a symposium preceding the 50th Annual Scientific Session of the American College of Cardiology from a study of patients with ST-segment elevation myocardial infarction (commonly referred to as heart attack) showed that the anti-platelet agent INTEGRILIN(R) combined with a half dose of the single-bolus fibrinolytic agent, TNKase(TM), fully restored blood flow through blocked arteries supplying oxygen-starved heart muscle in 70 percent of patients (n=47) within 60 minutes of initiation of therapy.
Retavase is a fibrinolytic agent used to treat patients who suffer from heart attacks.